Souptik Barua

Souptik Barua

Auto-generated profile, based on publicly available information

Souptik Barua

Division of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in eClinicalMedicine
Verified
Journal Article
Open access
SBSouptik Barua
Souptik Barua
ASAshutosh Sabharwal
Ashutosh Sabharwal
NGNamino Glantz
Namino Glantz
CCCasey Conneely
Casey Conneely
ALArianna Larez
Arianna Larez
DKDavid Kerr
David Kerr
Continuous glucose monitoring (CGM) has demonstrable benefits for people living with diabetes, but the supporting evidence is almost exclusively from White individuals with type 1 diabetes. Here, we have quantified CGM profiles in Hispanic/Latino adults with or at-risk of non-insulin treated type 2 diabetes (T2D). 100 participants (79 female, 86% Hispanic/Latino [predominantly Mexican], age 54·6 [±12·0] years) stratified into (i) at risk of T2D, (ii) with pre-diabetes (pre-T2D), and (iii) with non-insulin treated T2D, wore blinded CGMs for 2 weeks. Beyond standardized CGM measures (average glucose, glucose variability, time in 70–140 mg/dL and 70–180 mg/dL ranges), we also examined additional CGM measures based on the time of day. Standardized CGM measures were significantly different for participants with T2D compared to at-risk and pre-T2D participants (p<0·0001). In addition, pre-T2D participants spent more time between 140 and 180 mg/dL during the day than at-risk participants (p<0·01). T2D participants spent more time between 140 and 180 mg/dL both during the day and overnight compared to at-risk and pre-T2D participants (both p<0·0001). Time in 70–140 mg/dL range during the day was significantly correlated with HbA1c (r=-0·72, p<0·0001), after adjusting for age, sex, BMI, and waist circumference (p<0·0001). Standardized CGM measures show a progression of dysglycemia from at-risk of T2D, to pre-T2D, and to T2D. Stratifying CGM readings by time of day and the range 140–180 mg/dL provides additional metrics to differentiate between the groups. US Department of Agriculture (Grant #2018-33800-28404) and NSF PATHS-UP ERC (Award #1648451).

5 October 2020 in BMJ Nutrition, Prevention & Health
Verified
Journal Article
Open access
PDF file
DKDavid Kerr
David Kerr
SBSouptik Barua
Souptik Barua
NGNamino Glantz
Namino Glantz
CCCasey Conneely
Casey Conneely
MKMary Kujan
Mary Kujan
ASAshutosh Sabharwal
Ashutosh Sabharwal
Introduction: Poor diet is the leading cause of poor health in USA, with fresh vegetable consumption below recommended levels. We aimed to assess the impact of medical prescriptions for fresh (defined as picked within 72 hours) vegetables, at no cost to participants on cardiometabolic outcomes among adults (predominantly Mexican-American women) with or at risk of type 2 diabetes (T2D). Methods: Between February 2019 and March 2020, 159 participants (122 female, 75% of Mexican heritage, 31% with non-insulin treated T2D, age 52.5 (13.2) years) were recruited using community outreach materials in English and Spanish, and received prescriptions for 21 servings/week of fresh vegetable for 10 weeks. Pre-post comparisons were made of weight; waist circumference; blood pressure; Hemoglobin A 1c (HbA 1c , a measure of long-term blood glucose control); self-reported sleep, mood and pain; vegetable, tortilla and soda consumption. After obtaining devices for this study, 66 of 72 participants asked, agreed to wear blinded continuous glucose monitors (CGM). Results: Paired data were available for 131 participants. Over 3 months, waist circumference fell (−0.77 (95% CI −1.42 to 0.12) cm, p=0.022), as did systolic blood pressure (SBP) (−2.42 (95% CI −4.56 to 0.28) mm Hg, p=0.037), which was greater among individuals with baseline SBP >130 mm Hg (−7.5 (95% CI −12.4 to 2.6) mm Hg, p=0.005). Weight reduced by −0.4 (−0.7 to –0.04) kg, p=0.029 among women. For participants with baseline HbA 1c >7.0%, HbA 1c fell by −0.35 (-0.8 to –0.1), p=0.009. For participants with paired CGM data (n=40), time in range 70–180 mg/dL improved (from 97.4% to 98.9%, p<0.01). Food insecurity (p<0.001), tortilla (p<0.0001) and soda (p=0.013) consumption significantly decreased. Self-reported sleep, mood and pain level scores also improved (all p<0.01). Conclusions: Medical prescriptions for fresh vegetables were associated with clinically relevant improvements in cardiovascular risk factors and quality of life variables (sleep, mood and pain level) in adults (predominantly Mexican-American and female) with or at risk of T2D. Trial registration number: ClinicalTrials.gov Identifier: NCT03940300 .

1 July 2022 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
SBSouptik Barua
Souptik Barua
RWRaven A Wierzchowska-McNew
Raven A Wierzchowska-McNew
NDNicolaas E P Deutz
Nicolaas E P Deutz
ASAshutosh Sabharwal
Ashutosh Sabharwal
There has been growing interest in studying postprandial glucose responses using continuous glucose monitoring (CGM) in nondiabetic individuals. Accurate measurement of glucose responses to meals can facilitate applications such as precision nutrition and early detection of diabetes. We aimed to quantify the discordance between simultaneous postprandial glucose measurements made using plasma and CGM. We studied 10 nondiabetic older adults who randomly consumed 9 predefined meals of varying macronutrient compositions. Glucose was measured for 8 h after the meal by the CGM, blood samples for plasma collection were taken regularly, and plasma glucose was quantified using gold-standard laboratory measurement and a fingerstick blood glucose meter. The primary outcome measured was the mean absolute relative difference (MARD) of CGM and fingerstick measurements relative to the gold standard. Secondary outcomes were Bland–Altman statistics, Clarke Error Grid, and time in range metrics. Additional subgroup analyses were performed by stratifying the postprandial glucose measurements based on the macronutrient composition of the meals. When compared against the gold-standard postprandial glucose measurements, the fingerstick meter was more accurate (MARD: 8.0%; 95% CI: 7.6%, 8.6%) than the CGM (MARD: 13.7%; 95% CI: 13.1%, 14.3%; P < 0.0001). After the meals, Bland–Altman analysis demonstrated that the CGM underestimated the 8-h gold-standard glucose rise by 12.8 mg/dL on average (P < 0.0001), whereas the fingerstick meter did so by 5.5 mg/dL on average (P < 0.0001). The CGM underestimated the time spent in the 70–180 mg/dL range (P = 0.002) and overestimated the time spent <70 mg/dL (P < 0.0001) compared with the other 2 methods. We discovered discordance between gold standard, fingerstick, and CGM in measuring plasma glucose concentrations after a meal. Consequently, emerging applications of CGM in healthy individuals, such as precision nutrition and diabetes onset prediction, may need to account for these discordances. This trial was registered at clinicaltrials.gov as NCT04928872.

3 June 2025 in Diabetic Medicine
Verified
Journal Article
Open access
SBSouptik Barua
Souptik Barua
DUDhairya Upadhyay
Dhairya Upadhyay
LBLauren T. Berube
Lauren T. Berube
CPCollin J. Popp
Collin J. Popp
MCMargaret Curran
Margaret Curran
MSMary Ann Sevick
Mary Ann Sevick
Aims: To characterize changes in continuous glucose monitoring (CGM)‐derived time in tight range (TIR) measures in individuals with prediabetes or non‐insulin‐treated type 2 diabetes undergoing dietary weight loss intervention and to quantify the association between weight loss and TIR improvement. Methods: Data from the Personal Diet Study, a 6‐month behavioural weight loss intervention in adults with prediabetes or non‐insulin‐treated type 2 diabetes [HbA 1c ≤ 8.0% (64 mmol/mol), managed with diet alone or with metformin], was analysed. Participants wore a CGM for a maximum of 2 weeks at baseline and 6 months. Changes in overall, daytime (06:00 h–23:59 h) and overnight (00:00 h–05:59 h) time in 54–140 mg/dL or 3.0–7.8 mmol/L (TIR 54–140 ), 70–140 mg/dL or 3.9–7.8 mmol/L (TIR 70–140 ) and >140 mg/dL or >7.8 mmol/L (TAR >140 ) were analysed. The association between weight change and TIR change adjusted for demographic and clinical covariates was computed using linear regression. Results: Baseline and 6 months CGM data from 76 participants (63 ± 8 years, 62% female, 64% White, BMI 33 ± 5 kg/m 2 , HbA 1c 5.8 ± 0.6%) were analysed. Overall TIR 54–140 increased (3.3% [0.3, 6.3]%; p = 0.03), with improvement in daytime (3.8% [0.9, 6.8]%; p = 0.01) but not overnight TIR 54–140 (2.0% [−2.2, 6.1]%; p = 0.36). In adjusted analysis, every 5% points of weight loss was associated with a 3.2% points increase in overall TIR 54–140 ( p = 0.016), driven by a 3.5% points increase in daytime TIR 54–140 ( p = 0.006). Similar associations were found for TAR >140 but not TIR 70–140 . There were no associations between weight loss and change in any overnight TIR measure. Conclusion: Weight loss was associated with improved daytime TIR 54–140 and TAR >140 in individuals with prediabetes and non‐insulin‐treated type 2 diabetes undergoing dietary intervention. The daytime time in tight range measures can complement traditional markers like HbA1c, offering a more comprehensive view of glycaemic variations during dietary weight loss programmes for individuals with prediabetes and type 2 diabetes not on insulin.

14 May 2025 in American Heart Journal
Verified
Journal Article
Closed access
SBSouptik Barua
Souptik Barua
DUDhairya Upadhyay
Dhairya Upadhyay
ASAditya Surapaneni
Aditya Surapaneni
MGMorgan Grams
Morgan Grams
LJLior Jankelson
Lior Jankelson
SHSean Heffron
Sean Heffron

23 December 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SBSouptik Barua
Souptik Barua
DUDhairya Upadhyay
Dhairya Upadhyay
SPStephanie Pena
Stephanie Pena
RMRiley McConnell
Riley McConnell
AVAshwini Varghese
Ashwini Varghese
JDJohn A Dodson
John A Dodson
Background: Wearable accelerometers, which continuously record physical activity metrics, are commonly used in mobile health–enabled cardiac rehabilitation (mHealth-CR). The association between adherence to accelerometer use during mHealth-CR and improvement in clinical outcomes, such as functional capacity, is understudied. The emergence of artificial intelligence (AI) technology provides novel opportunities to investigate accelerometry use patterns in relation to mHealth-CR outcomes. Objective: In this study, we sought to use an AI clustering framework to identify distinct behavioral phenotypes of adherence to accelerometer use. We then aimed to quantify the association of these adherence phenotypes with functional capacity improvements in older adults undergoing mHealth-CR. Methods: We analyzed data from the RESILIENT (Rehabilitation at Home Using Mobile Health in Older Adults After Hospitalization for Ischemic Heart Disease) trial, the largest randomized clinical study to date comparing mHealth-CR versus usual care in older adults (aged ≥65 years). Intervention arm participants were instructed to wear a Fitbit accelerometer for the 3-month study duration. Adherence to accelerometer use was quantified as overall adherence (percentage of days worn) via k-means clustering AI-derived measures and compared with changes in 6-minute walk distance (6-MWD), adjusted for demographic and clinical covariates. Results: Among 271 participants with a mean age of 71 years (SD 8), of whom 198 (73%) were male, accelerometers were worn for an average of 76 days (95% confidence limits 73,78) over 3 months. Adjusted analyses showed a weak association between days of wear and improvement in 6-MWD, with every 30 additional days associated with an 11-meter improvement (P=.08). Our k-means clustering framework identified adherence phenotypes at two resolutions: low resolution (k=2 clusters) and high resolution (k=8 clusters). The consistently high adherence cluster trended toward a 24.6-meter improvement in 6-MWD compared to the low and declining adherence clusters (n=39; 95% CI 0.7-49.9; P=.06). The 8-cluster phenotyping revealed a richer set of adherence patterns, with the consistently high adherence cluster in this analysis having a 38.5-meter (95% CI 2.2-74.7; P=.04) improvement in 6-MWD than the low adherence cluster, as well as greater average daily steps over the 3-month intervention (mean 7518, SD 3415 vs mean 4800, SD 2920 steps; P=.008). Conclusions: A time-series AI clustering framework identified a range of behavioral phenotypes representing different degrees of adherence to accelerometer use. Regression analysis identified a weak association between the higher adherence phenotype and functional capacity improvement in older adults undergoing mHealth-CR. Our AI-derived accelerometry adherence phenotypes may offer a new approach to tailor mHealth-CR regimens to individual patients, potentially leading to better outcomes in this high-risk population. Trial Registration: ClinicalTrials.gov NCT03978130; https://clinicaltrials.gov/study/NCT03978130 International Registered Report Identifier (IRRID): RR2-10.2196/32163